We herein tested the effect of B-cell depletion on tolerance induction to FVIII in a mouse model of hemophilia A. Two subclasses of anti-mouse CD20 monoclonal antibodies with differential depletion effects were used.
Introduction
FVIII replacement therapy is used in hemophilia A patients for treatment of bleeding episodes or for prophylaxis. However, up to 1/3 of the patients develop anti-FVIII inhibitory antibodies (inhibitors), which renders this mode of therapy itself ineffective.
1 Hemophilia A patients who recently developed inhibitors (<10 BU) usually undergo immune tolerance induction (ITI) therapy, which requires regular (usually daily) high dose FVIII infusion for months to years. In many patients, inhibitors can eventually be eradicated by ITI therapy with the establishment of long-term tolerance to FVIII. Though ITI has been practiced in the clinic for decades, the mechanism of its action remains largely unknown, nor is there any animal model for this approach. Furthermore, 20-40% of patients still fail the therapy, which inevitably increases their morbidity and mortality. 2 Recently, B-cell depletion using rituximab, a mouse/human chimeric anti-CD20 monoclonal antibody 3 , has emerged as effective in eliminating inhibitor (s) in some hemophilia A patients who failed ITI . 4, 5 However, the evaluation of anti-CD20 therapy often is complicated in the clinical setting by concomitant use of other immune modulating drugs, such as hydrocortisone and IVIG. 4 Therefore, it is still not known whether B-cell depletion actually facilitated tolerance induction to FVIII or complemented
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Methods

Animals and reagents
FVIII
-/-mice (E16) on C57BL/6 background were maintained from the colony of Dr. Leon Hoyer at the American Red Cross. 6, 7 FoxP3-GFP/FVIII -/-mice were generated by crossing FoxP3-GFP knock-in mice 8 against E16 mice as described. 9 All animals were housed and bred in pathogen-free micro-isolator cages at the animal facilities operated by the University of We next tested the effect of B-cell depletion using IgG1 anti-CD20 on inhibitor formation and its potential for tolerance induction to FVIII in FVIII primed E16 mice. As outlined in figure 2A , we first primed the E16 mice (n=51) i.v. with four weekly therapeutic doses (0.2µg) of FVIII to more closely mimic the situation in hemophilia A patients. 6, 14 As shown in Supplemental Figure 1A , over 80% of the mice developed inhibitor titers up to 150 BU (mean = 30.7± 4.8 BU). Groups of mice were then treated with a single dose of either IgG1 anti-CD20 or isotype control IgG1, intravenously.
Compared with the control IgG, B-cell depletion using IgG1 anti-CD20 alone did not significantly decrease the inhibitor titer in the mice (supplemental Fig. 1B ). This is not surprising since CD20 is specifically expressed on the cell surface of pre-B to mature B cells, including memory This does not necessarily define failure of ITI, since the mice were only exposed to high dose FVIII for 19 days and this may not be long enough for achieving tolerance to FVIII. In addition, a temporary marked increase of inhibitor titer after initiation of ITI is also often seen in hemophilia A patients.
17
In contrast, the dramatic increase in inhibitor titer seen in the control group was largely prevented by the pretreatment of a single dose of IgG1 anti-CD20, which depleted most of FO B cells and spared MZ B cells (Fig. 2B , right panel). A similar result was also seen when the experiment was independently repeated with the more complete B-cell depletion using IgG2a anti-CD20 (Fig. 2D ). It is known that inhibitor formation is T cell dependent in both humans and mice, 6, [18] [19] [20] and it has been reported that B cells are required for optimal CD4 T cell function. 21 Thus, the elimination of the majority of B cells may be responsible for the lack of boosting.
To test if the remaining MZ B cells after the IgG1 anti-CD20 pretreatment are able to promote tolerance to FVIII, we re-challenged treated mice with FVIII three months after the initiation of B cell depletion using IgG1 anti-CD20, when the number of peripheral B cells had recovered 60 % or more.
After FVIII challenge, the inhibitor titers remained significantly lower in the IgG1 anti-CD20 group (Fig. 2C ). Importantly, after the mice were subcutaneously challenged with an unrelated antigen, OVA, there was no significant difference in anti-OVA antibody response between the two groups (data not shown).
It has been shown that MZ B cells are necessary for the systemic tolerance phenotype induced through an immune privileged site such as the eye. , not significant, compared to non-treated naïve mice (student's t test).
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